It has something like 500 million in cash, last reported 10Q. That may have something to do with the 3 billion market valuation. But...revenues? Hardly any. To my knowledge, there are only 3 additional drugs derived from cannabis. There have been others but either the FDA said, no mas, or the companies that developed them withdrew them. Not very effective or little response by medical doctors.
There is a subset of OTC companies claiming to be development stage drug companies, both US and Canadian. Obviously produce no revenues, sell lots of stock, get funding from accredited investors in exchange for preferred stock and warrants. Not much different from goodness knows how many like them trading on the NASDAQ, NYSE, and AMEX that belong to the biotech sector.
He looks at you like you owe him money.